The group also discovered that cyclin-dependent kinase inhibitor 2A (CDKN2A) null organoids demonstrated increased sensitivity to EZP01556, a protein arginine methyltransferase 5 (PRMT5) inhibitor, indicating a potential new treatment option for many HNSCC patients who harbored a loss of CDKN2A [172,173]. Here, PRMT5 is linked to head and neck squamous cell carcinoma.